Bio-Thera Solutions announced that on October 8, 2024, the company signed an authorization license, production, supply, and commercialization agreement with CStone Pharmaceuticals for BAT2206 injection. According to the agreement, Bio-Thera Solutions received a one-time payment of $10 million from CStone Pharmaceuticals on November 13, 2024, including $8.5 million upfront payment and $1.5 million milestone payment, totaling RMB 71.991 million. The receipt of this amount further replenished the company's cash reserve, providing support for the company's subsequent pipeline research and internationalization strategy.
百奥泰:收到吉瑞医药1000万美元首付款及里程碑付款
Bio-Thera Solutions: Received $10 million upfront payment and milestone payment from CStone Pharmaceuticals.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.